ClinicalTrials.gg

Program

Rimonabant

Also written as “rimonabant (SR141716)”, “Rimonabant (SR141716)” and “rimonabant”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Smoking Cessation · Fatty Liver · Post-Acute COVID-19 Syndrome, led by 2 companies.

Furthest: phase 3, since Jan 23, 200238 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi350 open or runningphase 3since Jan 23, 2002Jan 23, 2002none ahead
Sinfatin S.L33 open or runningphase 2since May 20, 2026May 20, 2026Aug 2027phase 2 · NCT07843108

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Jan 23, 2002.

  1. Dec 5, 20062 phase 3 studies in ObesitySanofi · NCT00408148, NCT00412698
  2. Feb 9, 2007Phase 3 study in ObesitySanofi · NCT00434096 · 915 enrolled · Japan
  3. Mar 19, 2007Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00449605 · 508 enrolled · United States, Chile, Denmark and more
  4. Apr 6, 20075 phase 3 studiesSanofi · NCT00458081, NCT00459173, NCT00458718 and 2 more
  5. Apr 10, 2007Phase 2 study in ObesitySanofi · NCT00459004 · 527 enrolled · Japan
  6. May 24, 20072 phase 3 studies in ObesitySanofi · NCT00478972, NCT00478595
  7. Jun 1, 20072 phase 3 studies in ObesitySanofi · NCT00481975, NCT00481923
  8. Oct 17, 2007Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00546325 · 358 enrolled · Australia
  9. Dec 18, 20072 phase 3 studies in Fatty LiverSanofi · NCT00577148, NCT00576667
  10. May 7, 20082 phase 3 studiesSanofi · NCT00690456, NCT00678483
  11. Sep 17, 2008Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT00754689 · United States
  12. May 20, 2026Sinfatin S.L's first study: phase 2 study in FatigueNew to Sinfatin S.LSinfatin S.L · NCT07843108 · 8 enrolled · Spain
  13. Oct 27, 2026Phase 2 study in Chronic StrokeSinfatin S.L · NCT07913763 · 80 planned · Spain
  14. Nov 3, 2026Phase 2 study in Post-Acute COVID-19 SyndromeSinfatin S.L · NCT07930637 · 80 planned · Spain

Ahead

  1. Aug 2027Primary completion: phase 2 study in FatigueSinfatin S.L · NCT07843108
  2. Jan 31, 2028Primary completion: phase 2 study in Chronic StrokeSinfatin S.L · NCT07913763
  3. Mar 2028Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeSinfatin S.L · NCT07930637

TargetBeta

CNR1 →read by rule
“Cannabinoid CB1 receptor antagonist”ChEMBL 37, by rule

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
CannabidiolruleJazz Pharmaceuticalsphase 468
DronabinolruleJazz Pharmaceuticalsphase 320
CRB-913rulecorbus-pharmaceuticals-incphase 11

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07930637Post-Acute COVID-19 Syndrome · Spain2Not yet recruitingSinfatin S.LMar 202880
NCT07913763Chronic Stroke · Spain2Not yet recruitingSinfatin S.LJan 31, 202880
NCT07843108Fatigue · Spain2Active, not recruitingSinfatin S.LAug 20278
NCT00754689Diabetes Mellitus, Type 2 · United States3WithdrawnSanofiNov 20080
NCT00678483Obesity · Croatia, Finland, Hungary and more3TerminatedSanofiNov 2008331
NCT00690456Diabetes Mellitus, Type 2 · United States, Indonesia, Lithuania and more3TerminatedSanofiFeb 2009403
NCT00577148Fatty Liver · United States, Argentina, Australia and more3TerminatedSanofiFeb 200989
NCT00576667Fatty Liver · United States, Argentina, Australia and more3TerminatedSanofiFeb 2009165
NCT00546325Diabetes Mellitus, Type 2 · Australia3CompletedSanofiFeb 2009358
NCT00481975Obesity · United States, Finland, France and more3CompletedSanofiAug 2005289
NCT00481923Obesity · United Kingdom3CompletedSanofiApr 2005156
NCT00478972Obesity · Japan3TerminatedSanofiJan 2009321
NCT00478595Obesity · Japan3TerminatedSanofiFeb 2009458
NCT00464256Smoking Cessation · United States3CompletedSanofiNov 2004533
NCT00464165Smoking Cessation · Belgium, Denmark, France and more3CompletedSanofiOct 2003789
NCT00459173Maintenance of Smoking Cessation · United States, Australia, Canada3CompletedSanofiSep 20054,850
NCT00459004Obesity · Japan2CompletedSanofiApr 2006527
NCT00458718Smoking Cessation · United States3CompletedSanofiJul 2005755
NCT00458081Obesity · Spain3TerminatedSanofiJan 2009174
NCT00449605Diabetes Mellitus, Type 2 · United States, Chile, Denmark and more3TerminatedSanofiNov 2008508
NCT00434096Obesity · Japan3TerminatedSanofiNov 2008915
NCT00412698Obesity · Czech Republic, Finland, Germany and more3TerminatedSanofiJan 2009645
NCT00408148Obesity · Australia, Finland, France and more3TerminatedSanofiDec 200864
NCT00405808Obesity · Austria, Belgium, Brazil and more3TerminatedSanofiFeb 20092,666
NCT00386061Obesity · United States, Belgium, Finland and more3CompletedSanofiJun 20041,507
NCT00358228Smoking Cessation · United States3CompletedSanofiAug 2003787
NCT00325650Prediabetic State · United States3TerminatedSanofiMar 20092,420
NCT00325546Obesity · China, Korea, Republic of, Taiwan3CompletedSanofiApr 2007643
NCT00299325Metabolic Syndrome · United States, Canada, Denmark and more3CompletedSanofiJul 2008254
NCT00288236Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedSanofiJul 2007368
NCT00263042Cardiovascular Diseases · United States, Argentina, Australia and more3TerminatedSanofiApr 200918,695
NCT00257257Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more3CompletedSanofiJun 2006281
NCT00239967Dyslipidemias · United States, Australia, Brazil and more3CompletedSanofiFeb 2007803
NCT00228176Carotid Stenosis · United States, Canada, France and more3TerminatedSanofiApr 2009661
NCT00124332Coronary Artery Disease · United States, Australia, Belgium and more3CompletedSanofiOct 2007839
NCT00029861Obesity · United States, Canada3CompletedSanofiApr 20043,045
NCT00029848Obesity · United States, Argentina, Belgium and more3CompletedSanofiMay 20041,045
NCT00029835Obesity · United States, Australia, Canada and more3CompletedSanofiNov 20031,033

How it is read

Names in the registry

  • “Rimonabant”, 19 entries
  • “rimonabant (SR141716)”, 8 entries
  • “Rimonabant (SR141716)”, 8 entries
  • “rimonabant”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.